tbuckley/cabot-search huggingface dataset:
Better Understanding of the Metamorphosis of Pregnancy (BUMP): protocol for a digital feasibility study in women from preconception to postpartum
Authors: S. M. Goodday, E. Karlin, A. Brooks, C. Chapman, D. R. Karlin, L. Foschini, E. Kipping, M. Wildman, M. Francis, H. Greenman, Li Li, E. Schadt, M. Ghassemi, A. Goldenberg, F. Cormack, N. Taptiklis, C. Centen, S. Smith, S. Friend
Journal: npj Digital Medicine (2022)

Abstract The Better Understanding the Metamorphosis of Pregnancy (BUMP) study is a longitudinal feasibility study aimed to gain a deeper understanding of the pre-pregnancy and pregnancy symptom experience using digital tools. The present paper describes the protocol for the BUMP study. Over 1000 participants are being recruited through a patient provider-platform and through other channels in the United States (US). Participants in a preconception cohort (BUMP-C) are followed for 6 months, or until conception, while participants in a pregnancy cohort (BUMP) are followed into their fourth trimester. Participants are provided with a smart ring, a smartwatch (BUMP only), and a smart scale (BUMP only) alongside cohort-specific study apps. Participant centric engagement strategies are used that aim to co-design the digital approach with participants while providing knowledge and support. The BUMP study is intended to lay the foundational work for a larger study to determine whether participant co-designed digital tools can be used to detect, track and return multimodal symptoms during the perinatal window to inform individual level symptom trajectories.
ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA
Authors: Michael J. Koren, Alexis Hofherr, Jennifer Schumi, Dinko Rekic, Jane Knochel, Catarina A.M. Nilsson, Anna Rudvik, Linda Wernevik, Tina Ryden-Bergsten, Bjorn C.L. Carlsson
Journal: Journal of the American College of Cardiology (2022)
Validating Deep Learning to Distinguish Takotsubo Syndrome From Acute Myocardial Infarction—Beware of Shortcuts, Human Supervision Required
Authors: Ramsey M. Wehbe, James D. Thomas
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
OUTCOMES FOLLOWING THE TREATMENT OF DIFFUSE CORONARY LESIONS WITH ONE LONG STENT RATHER THAN A MULTI-STENT STRATEGY: ONE-YEAR RETROSPECTIVE SINGLE CENTRE REVIEW. CASE SERIES
Authors: Hani Muradagha, Roisin Gardiner, Samir Morad, Amged Elsayed, Christopher Balfe, Tommy Hennessy, Ihsan Ullah, Samer Arnous, Terence Hennessy, Thomas Kiernan
Journal: Journal of the American College of Cardiology (2022)
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
Authors: Olga Minenkova, Daniela Santapaola, Ferdinando Maria Milazzo, Anna Maria Anastasi, Gianfranco Battistuzzi, Caterina Chiapparino, Antonio Rosi, Giuseppe Gritti, Gianmaria Borleri, Alessandro Rambaldi, Clélia Dental, Cécile Viollet, Bruno Pagano, Laura Salvini, Emanuele Marra, Laura Luberto, Antonio Rossi, Anna Riccio, Emilio Merlo Pich, Maria Gabriella Santoro, Rita De Santis
Journal: Molecular Therapy (2022)

As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single-chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the Delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. In two independent animal models, intranasal administration counteracted the infection. Because of their high efficiency, remarkable stability, resilience to nebulization, and low cost of production, 76clAbs may become a relevant tool for rapid, self-administrable early intervention in SARS-CoV-2-infected subjects independently of their immune status.
68Ga-Pentixafor PET/CT Improves the Detection of Recurrent Myeloma in the Temporal Bone Masked by the Physiological 18F-FDG Uptake of the Brain and Extraocular Muscles
Authors: Qingqing Pan, Yaping Luo, Xinxin Cao, Jian Li
Journal: Clinical Nuclear Medicine (2022)

Abstract A 71-year-old woman was recently diagnosed with multiple myeloma. Baseline 18 F-FDG and 68 Ga-pentixafor PET/CT showed diffusely increased uptake in bone marrow, consistent with infiltrated myeloma. She had very good partial response after 9 cycles of chemotherapy. However, during the maintenance with ixazomib, she experienced progressed disease. In the follow-up PET/CT, except for diffusely infiltrated disease in bone marrow, 68 Ga-pentixafor PET/CT additionally detected a new emerging lesion in the right temporal bone with lytic bone destruction, which was initially missed in 18 F-FDG PET/CT due to the intense physiological uptake of the brain and extraocular muscles.
Coronary Artery Calcium for Risk Stratification of Sudden Cardiac Death
Authors: Alexander C. Razavi, S.M. Iftekhar Uddin, Zeina A. Dardari, Daniel S. Berman, Matthew J. Budoff, Michael D. Miedema, Albert D. Osei, Olufunmilayo H. Obisesan, Khurram Nasir, Alan Rozanski, John A. Rumberger, Leslee J. Shaw, Laurence S. Sperling, Seamus P. Whelton, Martin Bødtker Mortensen, Michael J. Blaha, Omar Dzaye
Journal: JACC. Cardiovascular imaging (2022)
Advances in Estimating Mortality Associated With Tropical Cyclones in the US
Authors: James M. Shultz, Lori Peek, Sandro Galea
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SYNCHRONIZED VERSUS STAGED PERCUTANEOUS CORONARY INTERVENTION (PCI) REVASCULARIZATION STRATEGY PRIOR TO TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR): A META-ANALYSIS.
Authors: Ahmed Altibi, Fares H. Ghanem, Omar Al-Taweel, Faris Hammad, Mohammad Alshami, Hind Rahmouni
Journal: Journal of the American College of Cardiology (2022)
Multidisciplinary Ethics Review for Liminal Cases in Maternal-Fetal Surgery: A Model
Authors: Kirsten A. Riggan, Abigail Rousseau, Siobhan Pittock, Mauro Schenone, Leal Segura, Lindsay Warner, Megan A. Allyse
Journal: The American Journal of Bioethics (2022)

This article is referred to by:A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy Trials: Response to CommentariesFetal Therapies and Clinical Research: Beyond Risk and Benefit
Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
Authors: Ciaran N. Kohli-Lynch, James Lewsey, Kathleen A. Boyd, Dustin D. French, Neil Jordan, Andrew E. Moran, Naveed Sattar, David Preiss, Andrew H. Briggs
Journal: Circulation (2022)

Cholesterol guidelines typically prioritize primary prevention statin therapy on the basis of 10-year risk of cardiovascular disease. The advent of generic pricing may justify expansion of statin eligibility. Moreover, 10-year risk may not be the optimal approach for statin prioritization. We estimated the cost-effectiveness of expanding preventive statin eligibility and evaluated novel approaches to prioritization from a Scottish health sector perspective.A computer simulation model predicted long-term health and cost outcomes in Scottish adults ≥40 years of age. Epidemiologic analysis was completed using the Scottish Heart Health Extended Cohort, Scottish Morbidity Records, and National Records of Scotland. A simulation cohort was constructed with data from the Scottish Health Survey 2011 and contemporary population estimates. Treatment and cost inputs were derived from published literature and health service cost data. The main outcome measure was the lifetime incremental cost-effectiveness ratio, evaluated as cost (2020 GBP) per quality-adjusted life-year (QALY) gained. Three approaches to statin prioritization were analyzed: 10-year risk scoring using the ASSIGN score, age-stratified risk thresholds to increase treatment rates in younger individuals, and absolute risk reduction (ARR)-guided therapy to increase treatment rates in individuals with elevated cholesterol levels. For each approach, 2 policies were considered: treating the same number of individuals as those with an ASSIGN score ≥20% (age-stratified risk threshold 20, ARR 20) and treating the same number of individuals as those with an ASSIGN score ≥10% (age-stratified risk threshold 10, ARR 10).Compared with an ASSIGN score ≥20%, reducing the risk threshold for statin initiation to 10% expanded eligibility from 804 000 (32% of adults ≥40 years of age without CVD) to 1 445 500 individuals (58%). This policy would be cost-effective (incremental cost-effectiveness ratio, £12 300/QALY [95% CI, £7690/QALY-£26 500/QALY]). Incremental to an ASSIGN score ≥20%, ARR 20 produced ≈8800 QALYs and was cost-effective (£7050/QALY [95% CI, £4560/QALY-£10 700/QALY]). Incremental to an ASSIGN score ≥10%, ARR 10 produced ≈7950 QALYs and was cost-effective (£11 700/QALY [95% CI, £9250/QALY-£16 900/QALY]). Both age-stratified risk threshold strategies were dominated (ie, more expensive and less effective than alternative treatment strategies).Generic pricing has rendered preventive statin therapy cost-effective for many adults. ARR-guided therapy is more effective than 10-year risk scoring and is cost-effective.
Differences in Thickness-Specific Incidence and Factors Associated With Cutaneous Melanoma in the US From 2010 to 2018
Authors: Michael L. Chen, Isabella Joy de Vere Hunt, Esther M. John, Martin A. Weinstock, Susan M. Swetter, Eleni Linos
Journal: JAMA Oncology (2022)

Importance The recent incidence of cutaneous melanoma of different thicknesses in the US is not well described. Objective To evaluate recent patterns in the incidence of melanoma by tumor thickness and examine associations of sex, race and ethnicity, and socioeconomic status with melanoma thickness-specific incidence. Design, Setting, and Participants This population-based cohort study analyzed data for 187 487 patients with a new diagnosis of invasive cutaneous melanoma from the Surveillance, Epidemiology, and End Results Registry from January 1, 2010, to December 31, 2018. The study was conducted from May 27 to December 29, 2021. Data were analyzed from June 21 to October 24, 2021. Main Outcomes and Measures Age-adjusted incidence rates of melanoma were calculated by tumor thickness (categorized by Breslow thickness) and annual percentage change (APC) in incidence rates. Analyses were stratified by sex and race and ethnicity. The associations with socioeconomic status were evaluated in 134 359 patients diagnosed with melanoma from 2010 to 2016. Results This study included 187 487 patients with a median (IQR) age of 62 (52-72) years and 58.4% men. Melanoma incidence was higher in men compared with women across all tumor thickness groups. Individuals in lower socioeconomic status quintiles and members of minority groups were more likely to be diagnosed with thicker (T4) tumors (20.7% [169 of 816] among non-Hispanic Black patients, 11.2% [674 of 6042] among Hispanic patients, and 6.3% [10 774 of 170 155] among non-Hispanic White patients). Between 2010 and 2018, there was no significant increase in incidence of cutaneous melanoma across the full population (APC, 0.39%; 95% CI, –0.40% to 1.18%). The incidence of the thickest melanomas (T4, &gt;4.0 mm) increased between 2010 and 2018, with an APC of 3.32% (95% CI, 2.06%-4.60%) overall, 2.50% (95% CI, 1.27%-3.73%) in men, and 4.64% (95% CI, 2.56%-6.75%) in women. Conclusions and Relevance In this population-based cohort study, the incidence of the thickest cutaneous melanoma tumors increased from 2010 to 2018, in contrast with the incidence patterns for thinner melanomas. The findings suggest potential stabilization of overall melanoma incidence rates in the US after nearly a century of continuous increase in incidence. Patients with low socioeconomic status and Hispanic patients were more likely to be diagnosed with thick melanoma. The continued rise in incidence of thick melanoma is unlikely to be attributable to overdiagnosis given the stability of thin melanoma rates.
MACHINE-LEARNING FOR THE ASSESSMENT OF PATIENT PROSTHESIS MISMATCH IN PATIENTS WITH LOW GRADIENT SEVERE AORTIC STENOSIS UNDERGOING TAVR
Authors: Meghan Nahass, Ashok Chaudhary, David-Allen Lindsay, Shiochee Liang, Naveena Yanamala, Sabha Bhatti, Ankur Sethi, Abdul Hakeem, John Kassotis, Leonard Y. Lee, Mark Russo, Partho P. Sengupta
Journal: Journal of the American College of Cardiology (2022)
HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients
Authors: Priyanka Reddy, James Martin, Alberto Montero
Journal: Journal of the National Comprehensive Cancer Network (2022)

"HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Abstract TF1-2: ER+ word salad decoded: SERD, SERM, SERCA, CERAN, PROTAC
Authors: K Jhaveri
Journal: Cancer Research (2022)

Abstract Estrogen receptor (ER) plays an important role in gene transcription and the proliferation of ER positive (ER+) breast cancers. Selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and fulvestrant, a selective estrogen receptor degrader (SERD) are currently approved therapeutic approaches for ER positive breast cancers. While these treatment strategies are highly effective, de novo and secondary resistance remains a challenge. Despite resistance mechanisms including due to mutations in the ligand binding domain of the ERα gene (ESR1 mutations), ER+ breast cancers continue to rely on receptor activity for growth signaling, underscoring the need for more effective treatments. To overcome the limitations of the existing endocrine therapies, there has been a quest to develop more potent and selective ER antagonists by altering aspects of drug binding or induction of proteolytic degradation of the receptor through different mechanisms. These orally bioavailable agents offer the potential for low toxicity and improved activity and are in various phases of clinical development either as monotherapy or in combination with targeted therapies. Citation Format: K Jhaveri. ER+ word salad decoded: SERD, SERM, SERCA, CERAN, PROTAC [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr TF1-2.
Workforce Providing Abortion Care and Management of Pregnancy Loss in the US
Authors: Julia Strasser, Ellen Schenk, Kirsten Das, Jennifer Villavicencio, Rachel Banawa, Patricia Pittman, Candice Chen
Journal: JAMA Internal Medicine (2022)

Ushma D. Upadhyay, PhD, MPH; Elizabeth G. Raymond, MD, MPH; Leah R. Koenig, MSPH; Leah Coplon, CNM, MPH; Marji Gold, MD; Bliss Kaneshiro, MD, MPH; Christy M. Boraas, MD, MPH; Beverly Winikoff, MD, MPH
First-Line Immunotherapy for Non–Small-Cell Lung Cancer
Authors: Martin Reck, Jordi Remon, Matthew D. Hellmann
Journal: Journal of Clinical Oncology (2022)

For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that has contributed to substantially improved survival. In particular, the development of specific antibodies against the programmed death (PD-1) receptor, programmed death-ligand 1 (PD-L1), and the cytotoxic T-lymphocyte-associated protein 4 receptor in the therapeutic strategy of mNSCLC either in first- or in second-line settings have led to unprecedented prolonged survival for a proportion of these patients. Although clinical development of immune checkpoint inhibitors with anti-PD-1 and PD-L1 therapies largely began as monotherapy in the second-line setting, the more recent progress has shifted toward combination approaches in first-line settings as well as the integration of immunotherapy into the clinical paradigm in earlier stages. Today, with the exception of mNSCLC harboring targetable oncogenes, nearly all patients with mNSCLC receive PD-1 or PD-L1 therapy in first-line settings. Here we report the current status of first-line immunotherapy in mNSCLC together with current challenges in selecting the best immunotherapeutic approach for the individual patient.
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
Authors: Ben Killingley, Alex J. Mann, Mariya Kalinova, Alison Boyers, Niluka Goonawardane, Jie Zhou, Kate Lindsell, Samanjit S. Hare, Jonathan Brown, Rebecca Frise, Emma Smith, Claire Hopkins, Nicolas Noulin, Brandon Löndt, Tom Wilkinson, Stephen Harden, Helen McShane, Mark Baillet, Anthony Gilbert, Michael Jacobs, Christine Charman, Priya Mande, Jonathan S. Nguyen-Van-Tam, Malcolm G. Semple, Robert C. Read, Neil M. Ferguson, Peter J. Openshaw, Garth Rapeport, Wendy S. Barclay, Andrew P. Catchpole, Christopher Chiu
Journal: Nature Medicine (2022)
Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer
Authors: Tsukasa Masuda, Nobuyuki Tanaka, Kimiharu Takamatsu, Kyohei Hakozaki, Ryohei Takahashi, Tadatsugu Anno, Ryohei Kufukihara, Kazunori Shojo, Shuji Mikami, Toshiaki Shinojima, Kazuhiro Kakimi, Tatsuhiko Tsunoda, Eriko Aimono, Hiroshi Nishihara, Ryuichi Mizuno, Mototsugu Oya
Journal: Journal for ImmunoTherapy of Cancer (2022)

The aims of this study were (1) to clarify the impact of tertiary lymphoid structure (TLS) status on the outcome and immunogenomic profile of human clear cell renal cell carcinoma (ccRCC) and (2) to determine phenotypic differences in TLSs between different types of genitourinary cancer, that is, urinary ccRCC and bladder cancer.We performed a quantitative immunohistological analysis of ccRCC tissue microarrays and conducted integrated genome mutation analysis by next-generation sequencing and methylation array analysis. Since the tumor immune microenvironment of ccRCC often differs from that of other cancer types, we analyzed the phenotypic differences in TLSs between ccRCC and in-house bladder cancer specimens.Varying distribution patterns of TLSs were observed throughout ccRCC tumors, revealing that the presence of TLSs was related to poor prognosis. An analysis of genomic alterations based on TLS status in ccRCC revealed that alterations in the PI3K-mTOR pathway were highly prevalent in TLS-positive tumors. DNA methylation profiling also revealed distinct differences in methylation signatures among ccRCC samples with different TLS statuses. However, the TLS characteristics of ccRCC and bladder cancer markedly differed: TLSs had the exact opposite prognostic impact on bladder cancer as on ccRCC. The maturity and spatial distribution of TLSs were significantly different between the two cancer types; TLSs were more mature with follicle-like germinal center organization and likely to be observed inside the tumor in bladder cancer. Labeling for CD8, FOXP3, PD-1, and PD-L1 showed marked differences in the diversity of the immune microenvironment surrounding TLSs. The proportions of CD8-, FOXP3-, and PD-L1-positive cells were significantly higher in TLSs in bladder cancer than in TLSs in ccRCC; rather the proportion of PD-1-positive cells was significantly higher in TLSs in ccRCC than in TLSs in bladder cancer.The immunobiology of ccRCC is unique, and various cancerous phenomena conflict with that seen in other cancer types; therefore, comparing the TLS characteristics between ccRCC and bladder cancer may help reveal differences in the prognostic impact, maturity and spatial distribution of TLSs and in the immune environment surrounding TLSs between the two cancers.
Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial
Authors: Anna Forsberg, Marcus Westerberg, Chris Metcalfe, Robert Steele, Johannes Blom, Lars Engstrand, Kaisa Fritzell, Mikael Hellström, Lars-Åke Levin, Christian Löwbeer, Andreas Pischel, Ulf Strömberg, Sven Törnberg, Yvonne Wengström, Anders Ekbom, Lars Holmberg, Rolf Hultcrantz
Journal: The Lancet. Gastroenterology & hepatology (2022)
DIRECT ORAL ANTICOAGULANTS VERSUS VITAMIN K ANTAGONIST FOR LEFT VENTRICULAR THROMBUS: AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND COHORT STUDIES
Authors: Wasawat Vutthikraivit, Pavida Pachariyanon, Pattara Rattanawong, Prapaipan Putthapiban, Suvasini Lakshmanan, Paul Jae-Hyuk Lee, Elias Hanna
Journal: Journal of the American College of Cardiology (2022)
CLOSING THE SEPTAL DOOR FOR TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR: A REGISTRY STUDY
Authors: Adithya Thomas Mathews, Kapil Hemant Painter, Mohamed Hamed, Daniel Jacobs, Ramez Morcos, Hamza Lodhi, Brijeshwar Singh Maini, Houman Khalili
Journal: Journal of the American College of Cardiology (2022)